Bristol Myers cuts mid-stage NASH, anti-TIGIT programs
Bristol Myers Squibb disclosed Thursday at its R&D Day that it cut six programs, including mid-stage drug candidates for NASH and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
